-
-
-
-
-
-
-
BridgeBio Pharma (BBIO): Attruby approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
-
-
-
-
-
-
-
AbbVie (ABBV) Phase 2 Results for Emraclidine in Schizophrenia Did Not Meet their Primary Endpoint
-
-
-
-
-
-
-
Autonomix Medical (AMIX): Positive Preliminary Results Demonstrate Autonomix’s Proprietary RF Ablation Technology’s Ability to Reduce Opioid Use in Ongoing Human Clinical Trial
-
-
-
-
-
-
-
WAVE Life Sciences (WVE) Announces First-Ever Therapeutic RNA Editing in Humans Achieved in RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency
-
-
-
-
-
-
-
Avidity Biosciences Inc. (RNA) Announces FDA Removed Partial Clinical Hold on Delpacibart Etedesiran
-
-
-
-
-
-
-
Biohaven Pharma (BHVN) Reports Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia
-
-
-
-
-
-
-
Aligos Therapeutics Inc. (ALGS) Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH
-
5,662 total articles have been posted to this category.
Sign-up to StreetInsider.com Premium
to see all today's market moving Hot FDA News reports.